8-KThe WireRoutine
Company Update
Filed Jun 11, 2026 · 22d ago · Accession 0001193125-26-266705
Plain English
Silence Therapeutics plc issued a press release on June 11, 2026, highlighting follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran in patients with polycythemia vera.
Filing details
- Company
- Silence Therapeutics plc
- Ticker
- SLN
- CIK
- 1479615
- Form type
- 8-K
- Filing date
- Jun 11, 2026
- Report date
- Jun 11, 2026
- Document
- sln-20260611.htm
- Size
- 247 KB